Perfusion computed tomography in patients with hepatocellular carcinoma treated with thalidomide: Initial experience

Journal of Computer Assisted Tomography

Volumn 35, Issue 2, 2011, Pages 195-201

  Petralia, Giuseppe ^a   Fazio, Nicola ^a   Bonello, Luke ^b   D'Andrea, Gabriele ^b   Radice, Davide ^a   Bellomi, Massimo ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

hepatocellular carcinoma; perfusion computed tomography; predicting response to therapy; thalidomide; therapy monitoring

Indexed keywords

COMPUTERIZED TOMOGRAPHY; FORECASTING; HEMODYNAMICS; PATIENT TREATMENT; TUMORS;

BLOOD FLOW; BLOOD FLOW VOLUME; BLOOD VOLUMES; HEPATOCELLULAR CARCINOMA; PERFUSION COMPUTED TOMOGRAPHY; PREDICTING RESPONSE TO THERAPY; PROGRESSIVE DISEASE; THALIDOMIDE; THERAPY MONITORING; TUMOR SIZE;

BLOOD;

THALIDOMIDE;

ADULT; AGED; ARTICLE; BLOOD FLOW; BLOOD VOLUME; CANCER SIZE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER PERFUSION; MALE; OUTCOME ASSESSMENT; PERFUSION COMPUTER ASSISTED TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79953829674     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e31820ccf51     Document Type: Article

References (42)

1. Chowdhury S, Larkin JM, Gore ME. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer. 2008;44:2152-2161.
2. Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol. 2009;44(suppl 19):136-141.
3. Hegde SR, Sun W, Lynch JP. Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol. 2008;2:135-149.
4. Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol. 2009;2:2.
5. Podar K, Tai YT, Hideshima T, et al. Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009;14:99-127.
6. Rubegni P, Sbano P, De Aloe G, et al. Thalidomide in the treatment of Kaposi's sarcoma. Dermatology. 2007;215:240-244. (Pubitemid 47378993)
7. Garcia JA, Klein EA, Magi-Galluzzi C, et al. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res. 2008;14:3052-3059.
8. Han CJ. Recent developments in systemic chemotherapy for hepatocellular carcinoma. Korean J Hepatol. 2008;14:4-11.
9. Pinter M, Wichlas M, Schmid K, et al. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. Eur J Gastroenterol Hepatol. 2008;20:1012-1019.
10. Yau T, Chan P, Wong H, et al. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology. 2007;72(suppl 1):67-71. (Pubitemid 350256667)
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
12. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214. (Pubitemid 11167383)
13. Belton AL, Saini S, Liebermann K, et al. Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. Clin Radiol. 2003;58:311-314. (Pubitemid 36416974)
14. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006;24:3245-3251. (Pubitemid 46622065)
15. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002;94:883-893. (Pubitemid 34778087)
16. Bertolini F, Mancuso P, Shaked Y, et al. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today. 2007;12:806-812. (Pubitemid 47539970)
17. Blann AD, Woywodt A, Bertolini F, et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost. 2005;93:228-235.
18. Bisdas S, Baghi M, Smolarz A, et al. Quantitative measurements of perfusion and permeability of oropharyngeal and oral cavity cancer, recurrent disease, and associated lymph nodes using first-pass contrast-enhanced computed tomography studies. Invest Radiol. 2007;42:172-179. (Pubitemid 46232822)
19. Sitartchouk I, Roberts HC, Pereira AM, et al. Computed tomography perfusion using first pass methods for lung nodule characterization. Invest Radiol. 2008;43:349-358. (Pubitemid 351769892)
20. Petralia G, Bonello L, Viotti S, et al. CT perfusion in oncology: how to do it. Cancer Imaging. 2010;10:8-19.
21. Gandhi D, Chepeha DB, Miller T, et al. Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. AJNR Am J Neuroradiol. 2006;27:101-106. (Pubitemid 46939894)
22. Bellomi M, Petralia G, Sonzogni A, et al. CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology. 2007;244:486-493. (Pubitemid 47080881)
23. Sabir A, Schor-Bardach R, Wilcox CJ, et al. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol. 2008;191:133-139. (Pubitemid 351955217)
24. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-147. (Pubitemid 38524883)
25. Faria SC, Ng CS, Hess KR, et al. CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol. 2007;189:378-385. (Pubitemid 47195923)
26. Itoh S, Ikeda M, Achiwa M, et al. Late-arterial and portal-venous phase imaging of the liver with a multislice CT scanner in patients without circulatory disturbances: automatic bolus tracking or empirical scan delay? Eur Radiol. 2004;14:1665-1673.
27. Miles KA. Functional computed tomography in oncology. Eur J Cancer. 2002;38:2079-2084. (Pubitemid 35223245)
28. Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol. 2003;76(spec no 1):S36-S42.
29. Miles KA, Charnsangavej C, Lee FT, et al. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol. 2000;7:840-850.
30. Sahani DV, Kalva SP, Hamberg LM, et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology. 2005;234:785-792. (Pubitemid 40250822)
31. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998;58:1408-1416. (Pubitemid 28193601)
32. Zhu AX, Holalkere NS, Muzikansky A, et al. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist. 2008;13:120-125. (Pubitemid 351342575)
33. Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol. 2007;39:1489-1499. (Pubitemid 47031027)
34. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000;18:2593-2602. (Pubitemid 30432526)
35. Chiou HE, Wang TE, Wang YY, et al. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol. 2006;12:6955-6960.
36. Long X, Cao J, Shi L, et al. MSCT perfusion imaging and its correlation with perfusion parameters, survivin expression, MVD, and pathologic grade in hepatocellular carcinomas. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009;34:1096-1102.
37. Chen WX, Min PQ, Song B, et al. Single-level dynamic spiral CT of hepatocellular carcinoma: correlation between imaging features and density of tumor microvessels. World J Gastroenterol. 2004;10:67-72. (Pubitemid 38071980)
38. Matsui O. Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection. Intervirology. 2004;47:271-276. (Pubitemid 39279465)
39. Sahani DV, Holalkere NS, Mueller PR, et al. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue - initial experience. Radiology. 2007;243:736-743. (Pubitemid 46799427)
40. Ippolito D, Sironi S, Pozzi M, et al. Perfusion computed tomographic assessment of early hepatocellular carcinoma in cirrhotic liver disease: initial observations. J Comput Assist Tomogr. 2008;32:855-858.
41. Chang YC, Huang CS, Liu YJ, et al. Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. Phys Med Biol. 2004;49:3593-3602.
42. De Lussanet QG, Backes WH, Griffioen AW, et al. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;63:1309-1315. (Pubitemid 41628023)